Stock listing

KRX:476060 Onconic Therapeutics, Inc. (온코닉테라퓨틱스) 주가

Follow Onconic Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · KRX:476060

₩10,210 KRW -340 (-3.2%)

Close on Nov 20, 2026

Past year -37.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩10,150 – ₩10,720 KRWNov 20, 2026
Volume
102,286 sharesNov 20, 2026
Market cap
₩463.6B KRWAt the close on Nov 20, 2026 · price × 45.41M shares outstanding
52-week range
₩8,790.00 – ₩28,900 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩5.73B KRWMedian day 175,130 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Onconic Therapeutics, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:476060 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩10,210-340-3.2%₩10,500₩10,720₩10,150102,286
₩10,550+50+0.5%₩10,600₩11,250₩10,300235,086
₩10,500-1,500-12.5%₩11,770₩12,140₩10,500319,772
₩12,000-570-4.5%₩12,860₩12,860₩11,990110,096
₩12,570+270+2.2%₩12,370₩13,270₩12,370219,349
₩12,300-240-1.9%₩12,540₩12,820₩12,13097,961
₩12,540+440+3.6%₩12,050₩12,640₩12,050112,649
₩12,100+490+4.2%₩11,910₩12,220₩11,89097,113
₩11,610-70-0.6%₩11,520₩12,060₩11,470128,534
₩11,680-390-3.2%₩11,100₩12,090₩11,100159,995
₩12,070-60-0.5%₩12,300₩12,800₩11,980151,878
₩12,130+330+2.8%₩11,910₩12,130₩11,400151,734
₩11,800-590-4.8%₩12,190₩12,270₩11,700104,397
₩12,390+280+2.3%₩11,860₩12,490₩11,83099,458
₩12,110-510-4.0%₩12,480₩12,590₩11,950148,190
₩12,620-450-3.4%₩13,200₩13,290₩12,520153,329
₩13,070+300+2.3%₩12,910₩13,220₩12,91088,044
₩12,770+420+3.4%₩12,700₩13,150₩12,700114,466
₩12,350-590-4.6%₩12,610₩13,000₩12,350112,742
₩12,940-130-1.0%₩12,740₩13,200₩12,600108,427
₩13,070-700-5.1%₩13,650₩13,660₩13,030131,981
₩13,770+180+1.3%₩13,840₩14,120₩13,67081,321
₩13,590-270-1.9%₩14,000₩14,070₩13,30089,135
₩13,860-40-0.3%₩13,300₩13,900₩13,30069,968
₩13,900+1,120+8.8%₩12,900₩14,160₩12,900178,236
₩12,780-870-6.4%₩12,730₩13,030₩12,550191,667
₩13,650-60-0.4%₩13,710₩14,020₩13,430119,832
₩13,710-510-3.6%₩13,700₩14,010₩13,300192,145
₩14,220-650-4.4%₩14,920₩15,170₩14,220160,330
₩14,870-640-4.1%₩15,240₩15,290₩14,750177,272
₩15,510-90-0.6%₩15,890₩15,940₩15,380157,586
₩15,600-110-0.7%₩15,680₩15,910₩14,890165,286
₩15,710-210-1.3%₩16,060₩16,160₩15,540174,730
₩15,920+570+3.7%₩15,170₩16,000₩15,170310,768
₩15,350+20+0.1%₩15,570₩15,720₩15,300157,428
₩15,330-650-4.1%₩15,610₩15,670₩15,150242,765
₩15,980+850+5.6%₩16,120₩16,430₩15,780604,734
₩15,130+400+2.7%₩15,410₩15,590₩14,940372,242
₩14,730-320-2.1%₩15,070₩15,140₩14,660163,340
₩15,050+190+1.3%₩14,970₩15,320₩14,840141,480
₩14,860-260-1.7%₩15,360₩15,380₩14,800175,530
₩15,120+520+3.6%₩14,540₩15,320₩14,540231,321
₩14,600-100-0.7%₩14,660₩14,740₩14,420103,952
₩14,700+70+0.5%₩14,750₩15,600₩14,610368,440
₩14,630-320-2.1%₩14,690₩14,990₩14,450291,895
₩14,950-670-4.3%₩15,220₩15,460₩14,950221,353
₩15,620-470-2.9%₩16,010₩16,070₩15,380261,102
₩16,090+40+0.2%₩15,760₩16,310₩15,670270,295
₩16,050-240-1.5%₩16,340₩16,420₩16,000258,389
₩16,290-150-0.9%₩16,250₩16,390₩16,010295,382
₩16,440-670-3.9%₩16,800₩16,960₩16,140475,310
₩17,110+310+1.8%₩17,100₩17,580₩16,530822,021
₩16,800-1,190-6.6%₩17,560₩17,820₩16,800673,839
₩17,990-40-0.2%₩17,430₩18,440₩16,9002,945,540
₩18,030+3,260+22.1%₩15,200₩18,620₩14,8506,389,230
₩14,770+400+2.8%₩14,400₩14,880₩14,260262,751
₩14,370-90-0.6%₩14,380₩14,600₩14,190123,532
₩14,460+90+0.6%₩14,700₩14,900₩14,400188,581
₩14,370-150-1.0%₩14,150₩14,400₩13,820176,015
₩14,52000.0%₩14,550₩14,760₩14,220228,054
₩14,520-210-1.4%₩14,930₩14,940₩14,170376,814
₩14,730+730+5.2%₩14,830₩15,090₩14,230324,140

Splits

1 split · KRX:476060 · every price before a split is adjusted for it

DayRatioWhat
4-for-1Split
Ticker
KRX:476060
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
KRX
Currency
KRW

Latest news

All Onconic Therapeutics, Inc. news

Onconic Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
1 in all · newest Oct 30, 2025 · oldest 2025

Valuation

P/E 19.1× against a median of 11.8×: the highest of 3 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
₩401.0B KRW
P/E
19.1×
EV/sales
4.9×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
5.4×
Gross margin
100.0%
Operating margin
21.1%
Net margin
29.5%
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Onconic Therapeutics, Inc. · KRX:476060US$346.5MUS$299.7M19.1×4.9×n/a5.4×29.5%0.0×n/a
Puma Biotechnology Inc · NASDAQ:PBYIUS$364.5MUS$255.9M15.3×1.1×5.8×2.5×10.3%0.0×0.88
PureTech Health PLC · LSE:PRTCUS$364.3MUS$160.3Mn/a34.4×n/a0.9×n/a0.1×n/a
Lumosa Therapeutics Co Ltd · TPEX:6535US$362.3MUS$343.1Mn/a329×n/a9.7×n/a0.0×n/a
Aspen Neuroscience, Inc. · NASDAQ:ASPEUS$361.2MUS$288.8Mn/an/an/an/an/an/an/a
AbClon, Inc. · KRX:174900US$348.2MUS$321.1Mn/a80.9×n/a8.8×−328.3%0.0×n/a
Alector, Inc. · NASDAQ:ALECUS$347.6MUS$208.9M8.4×1.2×4.9×3.0×23.9%0.0×1.72
Gongwin Biopharm Holdings Co., Ltd. · TPEX:6617US$347.3MUS$296.6Mn/a232×n/a4.9×−389.6%0.0×n/a
Lyell Immunopharma, Inc. · NASDAQ:LYELUS$339.3MUS$196.5Mn/a13,099×n/a1.8×n/a0.2×1.51
Avacta Group PLC · LSE:AVCTUS$337.8MUS$337.2Mn/a2,281×n/a68.5×n/a5.3×n/a
Inovio Pharmaceuticals, Inc. · NASDAQ:INOUS$329.7MUS$7.56Bn/a25,303×3.4×n/an/an/a0.70
Median of the othersUS$347.9MUS$292.7M11.8×232×4.9×4.0×−159.0%0.0×1.20

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022
Revenue53.4B14.8B21.1B95.0M
Gross profit53.4B14.8B21.1B95.0M
Research and development9.72B10.9B15.8B13.2B
Selling, general and administrative28.2B6.14B1.20B492.0M
Operating income12.6B-4.80B2.23B-14.8B
Depreciation and amortization528.4M452.7M460.1M200.8M
EBITDA13.1B-4.35B2.69B-14.6B
Interest expense11.7M664.2M1.78B904.4M
Income before tax13.7B-9.94B661.8M-14.4B
Net income15.8B-8.09B1.68B-14.4B
Earnings per share, basic355.12-749.04155.73-1,335.80

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents47.0B43.0B30.1B27.3B
Short-term investments5.69B
Receivables10.5B7.33B104.5M
Current assets63.8B52.1B30.8B28.2B
Total assets75.7B60.9B37.5B30.9B
Accounts payable2.67B708.7M
Current liabilities3.62B4.77B57.0B26.6B
Total liabilities3.67B4.89B57.2B52.8B
Shareholders' equity72.0B56.0B-19.7B-21.9B
Shares outstanding44.4M10.8M10.8M10.8M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations11.4B-7.84B4.14B-15.0B
Capital spending-302.9M-141.3M-1.16B-2.58B
Free cash flow11.1B-7.98B2.98B-17.5B
Change in cash4.05B12.9B2.78B8.46B

Open Financials

Cap table

Built by 6ix from Onconic Therapeutics, Inc.’s releases

Common shares
45,407,840
Fully diluted
45,407,840

Fully diluted

LineShares
Common shares45,407,840

Share count over time

CountShares
Nov 22, 202645,407,840

Open Cap table

Shareholders

HolderSharesValueAs of
Goldman Sachs Innovate Equity ETF8,853US$112KMay 31, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about Onconic Therapeutics, Inc.